Company intelligence
A-Alpha Bio
The protein-protein interaction company
About A-Alpha Bio
A-Alpha Bio is a biotechnology platform company building the foundational data layer for AI-driven protein engineering. Through Atlas, its data platform, A-Alpha Bio provides biopharma companies and model builders with access to ground truth datasets, including affinity and structure, for training, benchmarking and validating AI protein models. Its experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously—a scale at least four orders of magnitude beyond that of existing biophysical methods. A-Alpha Bio also applies its data and models directly with select partners to engineer next-generation dual-specific and molecular glue therapeutics, and to discover and optimize differentiated biologics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design.
Verified activity
Signals from A-Alpha Bio
3 published signals
Presence & Recognition
A-Alpha Bio announced that Co-Founder and CTO Randolph Lopez will present on September 15 at 8am PT/11am ET about the Atlas VHH De Novo Design Benchmark and benchmarking leading models.
Reported by A-Alpha Bio
Presence & Recognition
A-Alpha Bio announced that Co-Founder and CTO Randolph Lopez will host a webinar on September 15 to discuss how structural data at scale improves de novo design hit rates 4x over industry-standard filtering.
Reported by A-Alpha Bio
People
A-Alpha Bio celebrated two team members at its recent Summer onsite, Leah Homad and Natasha Seelam, who received Spotlight and Values Awards.
Reported by A-Alpha Bio